MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), and its’ wholly-owned subsidiary, Biocannabix Health Corporation (the “BCX”), a company focused on international research and development for cannabinoids, nutraceuticals and medical food formulations, is pleased to announce the appointment of Dr. Wolfgang Renz as Chief Scientific Officer and Advisor.
Dr. Wolfgang Renz is a business executive with expertise in medical innovation and cross-industry convergence, and a practising physician. Dr. Renz holds an MD and PhD from the University of Freiburg Medical School in Germany, and graduated magna cum laude. Dr. Renz is currently a partner at Tarmes Capital in Montreal, Canada; is a Senior Lecturer Executive at the School of Management, Technology, and Law, University of Sankt Gallen, Switzerland; is an Adjunct Professor of Experimental Surgery in the Faculty of Medicine, McGill University, Montreal; and is a Lt. Colonel (Reserve) in the German Armed Forces Medical Services Command.
Dr. Renz has also been a Senior Research Fellow at the Healthcare Innovation & Technology Lab in New York City since 2012. From 2014 to 2015, he was President of International Business at Physicians Interactive Holdings Inc., a provider of online clinical resources for healthcare professionals, and from 2011 to 2014, Dr. Renz was Corporate Vice President of Boehringer Ingelheim GmbH, a leading international pharmaceutical company. Dr. Renz speaks German, English, and French. In addition to his extensive work in for-profit and academic sectors, Dr. Renz has also worked with the German Red Cross and the Peace Corps. Dr. Renz serves on the board of several private and public corporations.
Aurelio Useche, CEO of Relevium stated: “We are extremely excited to welcome Dr. Renz as the leading force behind all the current and on-going future scientific research and development initiatives at Biocannabix. In addition to his role as co-founder of IAM Health GmbH, Dr. Renz also runs a successful medical practice in Germany, where he uses a wide range of traditional and non-traditional therapeutical approaches for patients with critical care needs, including advanced forms of Cancer research and development. This perfectly aligns with the long-term vision of our company”.
Dr. Wolfgang Renz commented: “In addition to the combined opportunities with IAM Health GmbH, we are very excited to continue the research and development of specific cannabinoid formulations, nutraceuticals and medical food supplements, with a particular focus on pediatric applications. This is an area of development we are quite excited about, and I am delighted to be joining the Biocannabix team”.
About Relevium Technologies
Relevium Technologies Inc., is a publicly traded Company, focussed on international procurement, logistics, and delivery of Personal Protective Equipment (“PPE”) into the North American marketplace. Utilizing trusted vendors and suppliers, and integrating a comprehensive, state-of-the-art supply chain, Artificial Intelligence (“AI”), and Blockchain technology, enables a highly secure and compliant platform for delivery of PPE equipment to Governments, Hospitals, Foundations, and various Institutions.
Biocannabix Health Corporation, a wholly owned subsidiary of Relevium Technologies Inc., is focused on Paediatric and Geriatric applications of Cannabinoid formulations, nutraceuticals and medical food formulations. The principal business of the Company is pursuing ongoing Research and Development for the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and cannabinoid therapeutics.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals.
These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
For more information about this press release: Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com
Like us on Facebook
Follow us on Twitter
Follow us on LinkedIn